Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches

Download these expert-selected slides from a hematology symposium highlighting best practice strategies including NCCN guidelines for treating patients with acute myeloid leukemia.

Share

Program Content

Activities

Treating AML Without Targetable Tx
Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2021

Expires: December 12, 2022

AML With Targetable Tx
Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2021

Expires: December 09, 2022

AML Tx 2021 Summary Slides
ExpressPoints:
Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 22, 2021

Expires: December 21, 2022

Faculty

cover img faculity

Danielle M. Brander, MD

Medical Instructor
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

cover img faculity

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

cover img faculity

Daniel A. Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Supporters

Supported by educational grants from

AbbVie Inc.

Bristol Myers Squibb

Genentech, a member of the Roche Group